Does artichoke leaf extract lower cholesterol and help the liver?

ALE works through a few distinct mechanisms operating in parallel.

Cholesterol production: Luteolin and cynarin inhibit HMG-CoA reductase, the same enzyme that statin drugs target, though less potently. They also reduce the uptake of LDL particles into the bloodstream by upregulating LDL receptor activity in the liver². A meta-analysis of nine randomized trials found ALE reduced total cholesterol by an average of 17.6 mg/dL and LDL by 14.9 mg/dL, with larger reductions in those starting with higher baseline cholesterol¹.

Bile stimulation (choleretic effect): Cynarin is a strong bile stimulant. Bile is produced by the liver and used to emulsify dietary fats in the small intestine. When bile flow increases, so does the excretion of cholesterol through the digestive tract — an independent route for lowering circulating cholesterol. This same bile-stimulating action is what makes ALE particularly useful for bloating and sluggish digestion, especially after fatty meals.

Liver protection: Chlorogenic acid and luteolin are potent antioxidants that concentrate in liver tissue. They reduce oxidative stress in hepatocytes, inhibit the NLRP3 inflammasome (a key driver of chronic liver inflammation), and activate the Nrf2/HO-1 antioxidant pathway. In non-alcoholic fatty liver disease (NAFLD), a double-blind RCT found that 600 mg/day of ALE over two months significantly reduced liver size, lowered liver enzyme levels (ALT and AST), improved hepatic blood flow, and reduced LDL and triglycerides — with no adverse effects reported⁴.

Practical dosing and what to look for

Clinical trials have used doses ranging from 600 mg to 1800 mg per day, typically standardized to a minimum of 5% cynarin or 15% chlorogenic acids. The 600 mg dose used in the NAFLD trial is the most conservative effective dose; 1500–1800 mg/day was used in the metabolic syndrome oxidative stress trial⁷.

ALE is best taken before meals because of its choleretic (bile-stimulating) effect — taking it 20–30 minutes before eating may improve fat digestion and reduce post-meal bloating.

Note: Because ALE stimulates bile flow, it should be used cautiously in people with gallstones or bile duct obstruction, where increased bile movement could aggravate symptoms.

Digestive benefits in functional gut disorders

Beyond the lipid and liver effects, ALE has clinical data for functional dyspepsia and IBS. A multicentre placebo-controlled trial involving 247 patients with functional dyspepsia found that ALE significantly outperformed placebo on overall symptom scores and quality of life metrics over six weeks⁵. A post-marketing surveillance study found that 96% of IBS patients who completed a course of ALE rated it as equal to or better than whatever treatment they had previously used⁶.

The digestive benefit is likely a downstream consequence of better bile flow: more bile means improved fat digestion and less fermentation-driven gas and bloating in the lower gut.

See our milk thistle page for a related approach to liver support using silymarin, which works through overlapping but distinct pathways.

Cholesterol and lipids

The strongest evidence for ALE is in lipid-lowering. A 2018 systematic review and meta-analysis¹ pooled nine randomized controlled trials covering 702 participants. ALE supplementation produced statistically significant reductions in:

• Total cholesterol: weighted mean difference (WMD) −17.6 mg/dL (p < 0.001)
• LDL cholesterol: WMD −14.9 mg/dL (p = 0.011)
• Triglycerides: WMD −9.2 mg/dL (p = 0.011)

HDL did not change significantly. Effect sizes were larger in participants with higher baseline cholesterol, consistent with the idea that ALE's mechanism targets excess cholesterol production rather than normal physiological levels.

A companion review² confirmed these findings and identified dose-response relationships across human intervention studies, with doses of 2–3 g/day producing LDL reductions of 8–49 mg/dL across trials. The wide range reflects differences in baseline lipid levels, formulation, and duration. Key active compounds identified were luteolin (HMG-CoA inhibition, LDL receptor upregulation) and chlorogenic acid (antioxidant, bile stimulation).

Liver disease: NAFLD

A 2022 meta-analysis³ examining ALE's effects specifically in NAFLD patients pooled five RCTs (333 participants). Standardized mean differences (SMDs) from placebo were:

• ALT reduction: SMD 1.1 (p < 0.001)
• AST reduction: SMD 1.01 (p < 0.001)
• Total cholesterol: SMD 0.98
• LDL: SMD 0.96
• Triglycerides: SMD 0.95

These are large effect sizes by clinical standards. The meta-analysis was registered on PROSPERO (CRD42020182502) and concluded that ALE qualifies as an evidence-based hepatoprotective agent for NAFLD.

The 2018 pilot RCT⁴ (100 patients, 600 mg/day ALE vs. placebo, 2 months) provides granular clinical detail: ALE significantly improved hepatic vein blood flow as measured by Doppler ultrasound, reduced portal vein diameter (a marker of portal hypertension), reduced physical liver size, and lowered ALT, AST, total bilirubin, LDL, and triglycerides. The ultrasound measures are particularly noteworthy because they reflect structural changes in the liver rather than just biomarker changes.

Oxidative stress and metabolic syndrome

A 2018 double-blind RCT⁷ randomized 80 metabolic syndrome patients to 1800 mg/day ALE or placebo for 12 weeks. ALE significantly reduced oxidized-LDL (ox-LDL) compared to placebo (−266.8 vs. −129.5 ng/L, p < 0.05). Ox-LDL is the modified form of LDL cholesterol that initiates atherosclerotic plaque formation, so this reduction has direct cardiovascular relevance beyond what standard lipid panels measure.

Digestive disorders

The functional dyspepsia trial⁵ enrolled 247 patients at multiple centers and randomized them to ALE (320 mg three times daily with meals) or placebo for six weeks. The ALE group showed significantly greater overall symptom improvement (8.3 ± 4.6 vs. 6.7 ± 4.8, p < 0.01) and significantly greater improvement in quality of life on the Nepean Dyspepsia Index (−41.1 vs. −24.8, p < 0.01). The trial was well-blinded and used standardized patient-reported outcome measures.

The IBS surveillance study⁶ was observational (post-marketing, not placebo-controlled), making its results suggestive rather than definitive. However, 96% of IBS patients rating ALE as equal to or better than prior treatments is a practically meaningful finding that justified the authors' call for a formal RCT.

Evidence strength summary

The cholesterol and NAFLD evidence is robust: meta-analyses of multiple RCTs with consistent direction of effect. The dyspepsia evidence is solid (multicentre RCT). The IBS and oxidative stress evidence is preliminary but positive. ALE has a good safety profile across all trials — adverse events were rare, mild, and gastrointestinal in nature. The main limitation across studies is duration: most trials run 6–12 weeks, so long-term effects remain less characterized.